Bayzed Health (HKG:2609) booked a loss attributable to equity shareholders of 13 million yuan for 2025, narrowing from a loss of 13.5 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.
Shares of the oncology-focused healthcare services provider were up over 15% in Wednesday afternoon trade.
Loss per share was 0.01 yuan, unchanged from the prior year.
Revenue declined 5.8% to 1.12 billion yuan from 1.19 billion yuan in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments